BIIB PE Ratio & Valuation,Is BIIB Overvalued

BIIB Relative Valuation

BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIIB is overvalued; if below, it's undervalued.

Historical Valuation

Biogen Inc (BIIB) is now in the Fair zone, suggesting that its current forward PE ratio of 13.80 is considered Fairly compared with the five-year average of 14.15. The fair price of Biogen Inc (BIIB) is between 164.17 to 237.77 according to relative valuation methord.

Relative Value

Fair Zone

164.17-237.77

Current Price：186.91

Fair

13.80

10.49

EV/EBITDA

Biogen Inc. (BIIB) has a current EV/EBITDA of 10.49. The 5-year average EV/EBITDA is 10.35. The thresholds are as follows: Strongly Undervalued below 5.62, Undervalued between 5.62 and 7.99, Fairly Valued between 12.72 and 7.99, Overvalued between 12.72 and 15.09, and Strongly Overvalued above 15.09. The current Forward EV/EBITDA of 10.49 falls within the Historic Trend Line -Fairly Valued range.

11.78

EV/EBIT

Biogen Inc. (BIIB) has a current EV/EBIT of 11.78. The 5-year average EV/EBIT is 12.53. The thresholds are as follows: Strongly Undervalued below 7.36, Undervalued between 7.36 and 9.94, Fairly Valued between 15.12 and 9.94, Overvalued between 15.12 and 17.70, and Strongly Overvalued above 17.70. The current Forward EV/EBIT of 11.78 falls within the Historic Trend Line -Fairly Valued range.

2.83

Biogen Inc. (BIIB) has a current PS of 2.83. The 5-year average PS is 3.41. The thresholds are as follows: Strongly Undervalued below 1.78, Undervalued between 1.78 and 2.60, Fairly Valued between 4.22 and 2.60, Overvalued between 4.22 and 5.03, and Strongly Overvalued above 5.03. The current Forward PS of 2.83 falls within the Historic Trend Line -Fairly Valued range.

9.43

P/OCF

Biogen Inc. (BIIB) has a current P/OCF of 9.43. The 5-year average P/OCF is 11.48. The thresholds are as follows: Strongly Undervalued below 6.01, Undervalued between 6.01 and 8.75, Fairly Valued between 14.22 and 8.75, Overvalued between 14.22 and 16.95, and Strongly Overvalued above 16.95. The current Forward P/OCF of 9.43 falls within the Historic Trend Line -Fairly Valued range.

11.79

P/FCF

Biogen Inc. (BIIB) has a current P/FCF of 11.79. The 5-year average P/FCF is 13.21. The thresholds are as follows: Strongly Undervalued below 6.77, Undervalued between 6.77 and 9.99, Fairly Valued between 16.43 and 9.99, Overvalued between 16.43 and 19.65, and Strongly Overvalued above 19.65. The current Forward P/FCF of 11.79 falls within the Historic Trend Line -Fairly Valued range.

Biogen Inc (BIIB) has a current Price-to-Book (P/B) ratio of 1.43. Compared to its 3-year average P/B ratio of 1.98 , the current P/B ratio is approximately -27.69% higher. Relative to its 5-year average P/B ratio of 2.58, the current P/B ratio is about -44.39% higher. Biogen Inc (BIIB) has a Forward Free Cash Flow (FCF) yield of approximately 8.83%. Compared to its 3-year average FCF yield of 6.53%, the current FCF yield is approximately 35.36% lower. Relative to its 5-year average FCF yield of 6.89% , the current FCF yield is about 28.19% lower.

1.43

P/B

Median3y

1.98

Median5y

2.58

8.83

FCF Yield

Median3y

6.53

Median5y

6.89

Competitors Valuation Multiple

The average P/S ratio for BIIB's competitors is 37.05, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of 2.83, which is -92.36% above the industry average. Given its robust revenue growth of 2.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of BIIB increased by 29.86% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 15.76 to 18.40.

The secondary factor is the P/E Change, contributed 10.32%to the performance.

Overall, the performance of BIIB in the past 1 year is driven by Margin Expansion. Which is more sustainable.

2.79%

2.47B → 2.53B

Revenue Growth

16.75%

15.76 → 18.40

Margin Expansion

10.32%

14.69 → 16.20

P/E Change

29.86%

143.93 → 186.91

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Biogen Inc (BIIB) currently overvalued or undervalued?

What is Biogen Inc (BIIB) fair value?

BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Biogen Inc (BIIB) is between 164.17 to 237.77 according to relative valuation methord.

How does BIIB's valuation metrics compare to the industry average?

What is the current P/B ratio for Biogen Inc (BIIB) as of Jan 08 2026?

As of Jan 08 2026, Biogen Inc (BIIB) has a P/B ratio of 1.43. This indicates that the market values BIIB at 1.43 times its book value.

What is the current FCF Yield for Biogen Inc (BIIB) as of Jan 08 2026?

As of Jan 08 2026, Biogen Inc (BIIB) has a FCF Yield of 8.83%. This means that for every dollar of Biogen Inc’s market capitalization, the company generates 8.83 cents in free cash flow.

What is the current Forward P/E ratio for Biogen Inc (BIIB) as of Jan 08 2026?

As of Jan 08 2026, Biogen Inc (BIIB) has a Forward P/E ratio of 13.80. This means the market is willing to pay $13.80 for every dollar of Biogen Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Biogen Inc (BIIB) as of Jan 08 2026?

As of Jan 08 2026, Biogen Inc (BIIB) has a Forward P/S ratio of 2.83. This means the market is valuing BIIB at $2.83 for every dollar of expected revenue over the next 12 months.

BIIB Valuation